Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics, Inc. reported that Chief Executive Officer Douglas Ingram has decided to retire. On February 25, 2026, he informed the company that he plans to step down by the end of 2026 or once a successor is appointed.
The company has begun a formal search process, considering both internal and external candidates to identify its next CEO. This filing does not discuss changes to the company’s strategy or operations, focusing solely on the planned leadership transition timeline.
Sarepta Therapeutics reported strong 2025 revenue growth but a sharp swing to losses as it invested heavily in gene therapy and RNAi programs. Full-year revenue rose to $2,198.2M from $1,902.0M, driven by ELEVIDYS and higher collaboration and manufacturing revenue, including milestones from Roche and Japan.
Despite this, Sarepta posted a GAAP net loss of $713.4M versus $235.2M of net income in 2024, with diluted EPS moving from $2.34 to a loss of $7.13. The decline reflects a surge in cost of sales, including a $165.3M inventory reserve and additional write-offs, plus research and development expenses of $1,522.1M tied to the Arrowhead DM1 collaboration and milestones.
Year-end cash, cash equivalents and investments were $953.8M. Sarepta refinanced $291.4M of 2027 convertible notes into 2030 notes with cash, reducing near-term maturities. Management highlighted positive three-year EMBARK data for ELEVIDYS, launch in Japan via Chugai, and advancement of multiple siRNA programs, and said it anticipates remaining profitable and cash-flow positive in 2026.
AQR Capital Management Holdings, LLC and AQR Capital Management, LLC report beneficial ownership of 8,104,869 shares of Sarepta Therapeutics, Inc. common stock, representing 7.73 % of the class as of 12/31/2025.
The position includes Convertible Notes representing 308,334 shares of common stock. The AQR entities report shared voting and shared dispositive power over all 8,104,869 shares, with no sole voting or dispositive authority.
They certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Sarepta Therapeutics. AQR Capital Management, LLC is a wholly owned subsidiary of AQR Capital Management Holdings, LLC.
Sarepta Therapeutics, Inc. filed a Form 13F as an institutional investment manager. The filing lists 1 Form 13F information table entry and reports a total table value of $0. The report is signed by Ryan Wong, Executive Vice President and Chief Financial Officer, dated 02-12-2026.
Sarepta Therapeutics director Claude Nicaise exercised stock options and adjusted his shareholdings. On January 29, 2026, he exercised 10,500 stock options at $13.71 per share, receiving 10,500 shares of common stock.
On the same date, 6,780 common shares were withheld by Sarepta, noted as satisfying payment of the option exercise price. After these transactions, Nicaise directly owned 31,532 shares of Sarepta common stock.
Sarepta Therapeutics director M. Kathleen Behrens reported an option exercise and related share withholding. On January 27, 2026, she exercised a stock option for 10,500 shares of common stock at $13.71 per share, converting a derivative award into owned stock.
To cover the option exercise cost, 6,494 shares of common stock were withheld by Sarepta at a price of $22.17 per share, as explained in the footnote. After these transactions, she held 197,482 shares of common stock directly and 10,000 shares indirectly through a trust.
BlackRock, Inc. filed an amended ownership report showing it beneficially owns 13,232,652 shares of Sarepta Therapeutics common stock, representing 12.6% of the class as of 12/31/2025. BlackRock reports sole voting power over 12,913,969 shares and sole dispositive power over the full 13,232,652 shares, with no shared voting or dispositive authority.
The filing aggregates holdings of certain BlackRock business units and notes that one holder, iShares Core S&P Small-Cap ETF, has an interest exceeding five percent of Sarepta’s outstanding common stock. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Sarepta, other than permitted nomination-related activities.
Sarepta Therapeutics, Inc. furnished a current report to share that it issued a press release with certain business updates and preliminary financial information for the year and fiscal quarter ended December 31, 2025. The disclosure was made in connection with the 44th Annual J.P. Morgan Healthcare Conference, highlighting recent operational and financial developments.
The press release is included as Exhibit 99.1 to the report and is incorporated by reference. The company specifies that this information is being furnished under Item 2.02, rather than filed, which limits how it is treated under securities law unless another filing specifically incorporates it by reference.
Sarepta Therapeutics plans a private exchange of approximately $291.4 million of its 1.25% Convertible Senior Notes due 2027 for the same principal amount of new 4.875% Convertible Senior Notes due 2030 plus about $31.6 million in cash.
The new notes will be issued as additional notes under Sarepta’s existing 4.875% 2030 convertible notes indenture, bringing the total principal of that series to $893.4 million after closing, which is expected on or about December 18, 2025, subject to customary conditions. The exchange, which includes participation by a trust affiliated with director Michael Chambers, is limited to institutional accredited investors and qualified institutional buyers under a private placement exemption, and the new notes and underlying shares will not be registered for public resale.
Sarepta Therapeutics, Inc. (SRPT) reported an insider equity transaction by its President, R&D and Tech Ops, filed on a Form 4. On 11/17/2025, the officer had 4,582 shares of common stock withheld by the company at a price of $18.42 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding transaction, the officer directly beneficially owned 224,030 shares of Sarepta common stock.